A statistical approach to central monitoring of data quality in clinical trials

Background Classical monitoring approaches rely on extensive on-site visits and source data verification. These activities are associated with high cost and a limited contribution to data quality. Central statistical monitoring is of particular interest to address these shortcomings. Purpose This article outlines the principles of central statistical monitoring and the challenges of implementing it in actual trials. Methods A statistical approach to central monitoring is based on a large number of statistical tests performed on all variables collected in the database, in order to identify centers that differ from the others. The tests generate a high-dimensional matrix of p-values, which can be analyzed by statistical methods and bioinformatic tools to identify extreme centers. Results Results from actual trials are provided to illustrate typical findings that can be expected from a central statistical monitoring approach, which detects abnormal patterns that were not (or could not have been) detected by on-site monitoring. Limitations Central statistical monitoring can only address problems present in the data. Important aspects of trial conduct such as a lack of informed consent documentation, for instance, require other approaches. The results provided here are empirical examples from a limited number of studies. Conclusion Central statistical monitoring can both optimize on-site monitoring and improve data quality and as such provides a cost-effective way of meeting regulatory requirements for clinical trials.

[1]  Canary Wharf,et al.  Reflection paper on risk based quality management in clinical trials , 2013 .

[2]  Hans-Christoph Diener,et al.  European Stroke Prevention Study 2. Efficacy and safety data. , 1997, Journal of the neurological sciences.

[3]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[4]  Taghrid Obied,et al.  Oversight of clinical investigations- A risk based approach to monitoring , 2014 .

[5]  P. Lachenbruch,et al.  The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, Statistics in medicine.

[6]  Sheena McCormack,et al.  The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial , 2012, Clinical trials.

[7]  T. Hill A Statistical Derivation of the Significant-Digit Law , 1995 .

[8]  Douglas G Altman,et al.  Ensuring trial validity by data quality assurance and diversification of monitoring methods , 2008, Clinical trials.

[9]  W. Härdle,et al.  Applied Multivariate Statistical Analysis , 2003 .

[10]  S. Lock,et al.  Fraud and Misconduct in Biomedical Research , 2019 .

[11]  James D Neaton,et al.  Monitoring the quality of conduct of clinical trials: a survey of current practices , 2011, Clinical trials.

[12]  Christian Ohmann,et al.  Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials , 2009, Clinical trials.

[13]  M. Buyse,et al.  Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer , 2006, Clinical trials.

[14]  I. Roberts,et al.  Carbon cost of pragmatic randomised controlled trials: retrospective analysis of sample of trials , 2009, BMJ : British Medical Journal.

[15]  David Moher,et al.  The Good Clinical Practice guideline: a bronze standard for clinical research , 2005, The Lancet.

[16]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[17]  J. Abraham The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[18]  Marc Buyse,et al.  Fraud in Clinical Trials , 2005 .

[19]  Peter Sandercock,et al.  Sensible approaches for reducing clinical trial costs , 2008, Clinical trials.